South Street Advisors LLC Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO

Key Points

• South Street Advisors LLC reduced its Halozyme Therapeutics stake by 6.5% in the fourth quarter, but still held 231,758 shares worth about $15.6 million as of its latest filing.
• Halozyme reported strong quarterly results, with EPS of $1.60 topping estimates and revenue of $376.71 million, up 42.2% year over year. The company also raised its FY2026 EPS guidance to 7.75–8.25.
• Wall Street remains broadly positive on HALO: analysts currently have a Moderate Buy consensus rating, with an average price target of $80.67, while several firms recently reaffirmed or raised their ratings and targets.

South Street Advisors LLC cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 231,758 shares of the biopharmaceutical company's stock after selling 16,094 shares during the quarter. Halozyme Therapeutics comprises 2.2% of South Street Advisors LLC's investment portfolio, making the stock its 21st largest holding. South Street Advisors LLC owned approximately 0.20% of Halozyme Therapeutics worth $15,597,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Root Financial Partners LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at approximately $25,000. Larson Financial Group LLC increased its position in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 343 shares during the period. Clearstead Advisors LLC increased its position in shares of Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company's stock valued at $37,000 after purchasing an additional 265 shares during the period. Harbour Investments Inc. increased its stake in Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 372 shares during the period. Finally, Penserra Capital Management LLC bought a new stake in Halozyme Therapeutics in the third quarter valued at about $52,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HALO. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 12th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Benchmark upped their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, May 16th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $80.67.

Halozyme Therapeutics Trading Down 0.7%

NASDAQ:HALO opened at $68.18 on Friday. The company has a market cap of $8.09 billion, a P/E ratio of 24.53, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The business has a 50 day moving average price of $66.09 and a two-hundred day moving average price of $68.77.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same period last year, the business posted $1.11 EPS. Halozyme Therapeutics's revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the company's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director directly owned 38,498 shares in the company, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at $49,322,187.20. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 120,482 shares of company stock valued at $8,200,842 over the last quarter. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.